Phase II Study of the Response Rate of Induction Chemotherapy With Gemcitabine and Carboplatin for Operable Non-small Cell Lung Cancer Before Surgery
Interventional
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
pathological response rate
12 months
Siu Kie Au, Dr
Principal Investigator
Department of Clinical Oncology, Queen Elizabeth Hospital
Hong Kong: Ethics Committee
(193-h)in QE/EC/I
NCT00563160
May 2005
February 2007
Name | Location |
---|